Genotype-based recall to study metabolic effects of genetic variation: a pilot study of PPARG Pro12Ala carriers

  • Prasad G. Kamble Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Sweden
  • Stefan Gustafsson Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Sweden
  • Maria J. Pereira Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Sweden
  • Per Lundkvist Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Sweden
  • Naomi Cook Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Sweden
  • Lars Lind Department of Medical Sciences, Molecular Epidemiology, EpiHealth, Uppsala University, Sweden
  • Paul W. Franks Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, Malmö, Sweden
  • Tove Fall Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Sweden
  • Jan W. Eriksson Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Sweden
  • Erik Ingelsson Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Sweden; and Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, USA
Keywords: Genotype-based recall, metabolism, PPARG Pro12Ala

Abstract

Aim: To assess practical implications of genotype-based recall (GBR) studies, an increasingly popular approach for in-depth characterization of genotype–phenotype relationships.

Methods: We genotyped 2500 participants from the Swedish EpiHealth cohort and considered loss-of-function and missense variants in genes with relation to cardiometabolic traits as the basis for our GBR study. Therefore, we focused on carriers and non-carriers of the PPARG Pro12Ala (rs1801282) variant, as it is a relatively common variant with a minor allele frequency (MAF) of 0.14. It has also been shown to affect ligand binding and transcription, and carriage of the minor allele (Ala12) is associated with a reduced risk of type 2 diabetes. We re-invited 39 Pro12Pro, 34 Pro12Ala, and 30 Ala12Ala carriers and performed detailed anthropometric and serological assessments.

Results: The participation rates in the GBR study were 31%, 44%, and 40%, and accordingly we included 12, 15, and 13 individuals with Pro12Pro, Pro12Ala, and Ala12Ala variants, respectively. There were no differences in anthropometric or metabolic variables among the different genotype groups.

Conclusions: Our report highlights that from a practical perspective, GBR can be used to study genotype–phenotype relationships. This approach can prove to be a valuable tool for follow-up findings from large-scale genetic discovery studies by undertaking detailed phenotyping procedures that might not be feasible in large studies. However, our study also illustrates the need for a larger pool of genotyped or sequenced individuals to allow for selection of rare variants with larger effects that can be examined in a GBR study of the present size.

Downloads

Download data is not yet available.
Published
2018-01-05
How to Cite
Kamble P. G., Gustafsson S., Pereira M. J., Lundkvist P., Cook N., Lind L., Franks P. W., Fall T., Eriksson J. W., & Ingelsson E. (2018). Genotype-based recall to study metabolic effects of genetic variation: a pilot study of PPARG Pro12Ala carriers. Upsala Journal of Medical Sciences, 122(4), 234–242. https://doi.org/10.1080/03009734.2017.1405127
Section
Original Articles